JPS62234026A - Food for patient of hepatic function disorder - Google Patents
Food for patient of hepatic function disorderInfo
- Publication number
- JPS62234026A JPS62234026A JP61074156A JP7415686A JPS62234026A JP S62234026 A JPS62234026 A JP S62234026A JP 61074156 A JP61074156 A JP 61074156A JP 7415686 A JP7415686 A JP 7415686A JP S62234026 A JPS62234026 A JP S62234026A
- Authority
- JP
- Japan
- Prior art keywords
- food
- improving
- genus
- fomes
- hepatic function
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000013305 food Nutrition 0.000 title claims abstract description 41
- 206010019670 Hepatic function abnormal Diseases 0.000 title abstract description 5
- 241000221198 Basidiomycota Species 0.000 claims abstract description 16
- 235000021107 fermented food Nutrition 0.000 claims abstract description 12
- 244000046052 Phaseolus vulgaris Species 0.000 claims abstract description 11
- 235000010627 Phaseolus vulgaris Nutrition 0.000 claims abstract description 11
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims abstract description 11
- 229930182490 saponin Natural products 0.000 claims abstract description 11
- 150000007949 saponins Chemical class 0.000 claims abstract description 11
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 claims abstract description 7
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 claims abstract description 7
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 claims abstract description 7
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 claims abstract description 7
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 claims abstract description 7
- FYGDTMLNYKFZSV-WFYNLLPOSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,3s,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-WFYNLLPOSA-N 0.000 claims abstract description 6
- 229920002498 Beta-glucan Polymers 0.000 claims abstract description 6
- 208000019423 liver disease Diseases 0.000 claims description 14
- 230000005976 liver dysfunction Effects 0.000 claims description 12
- 208000014617 hemorrhoid Diseases 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 14
- 244000061456 Solanum tuberosum Species 0.000 abstract description 10
- 235000002595 Solanum tuberosum Nutrition 0.000 abstract description 10
- 235000012015 potatoes Nutrition 0.000 abstract description 10
- 235000013339 cereals Nutrition 0.000 abstract description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract description 6
- 208000006454 hepatitis Diseases 0.000 abstract description 5
- 239000007788 liquid Substances 0.000 abstract description 5
- 230000036541 health Effects 0.000 abstract description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract description 3
- 229910052799 carbon Inorganic materials 0.000 abstract description 3
- 238000000855 fermentation Methods 0.000 abstract description 3
- 230000004151 fermentation Effects 0.000 abstract description 3
- 231100000283 hepatitis Toxicity 0.000 abstract description 3
- 229910052757 nitrogen Inorganic materials 0.000 abstract description 3
- 235000015097 nutrients Nutrition 0.000 abstract description 3
- 208000024891 symptom Diseases 0.000 abstract description 3
- 241000123326 Fomes Species 0.000 abstract 4
- 241000233866 Fungi Species 0.000 abstract 1
- 235000005911 diet Nutrition 0.000 abstract 1
- 230000037213 diet Effects 0.000 abstract 1
- 235000019629 palatability Nutrition 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 description 12
- 235000016709 nutrition Nutrition 0.000 description 12
- 239000000843 powder Substances 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 244000068988 Glycine max Species 0.000 description 8
- 235000010469 Glycine max Nutrition 0.000 description 8
- 239000000284 extract Substances 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 230000000144 pharmacologic effect Effects 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 6
- 150000001720 carbohydrates Chemical class 0.000 description 6
- 235000014633 carbohydrates Nutrition 0.000 description 6
- 240000006509 Gynostemma pentaphyllum Species 0.000 description 5
- 239000000306 component Substances 0.000 description 5
- 238000012258 culturing Methods 0.000 description 5
- 235000012041 food component Nutrition 0.000 description 5
- 239000012533 medium component Substances 0.000 description 5
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 235000013402 health food Nutrition 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 150000002772 monosaccharides Chemical class 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 4
- 240000008620 Fagopyrum esculentum Species 0.000 description 3
- 235000009419 Fagopyrum esculentum Nutrition 0.000 description 3
- 241000195888 Physcomitrella Species 0.000 description 3
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 3
- 235000019658 bitter taste Nutrition 0.000 description 3
- 208000019425 cirrhosis of liver Diseases 0.000 description 3
- 235000013312 flour Nutrition 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 244000075850 Avena orientalis Species 0.000 description 2
- 235000007319 Avena orientalis Nutrition 0.000 description 2
- 235000007558 Avena sp Nutrition 0.000 description 2
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 2
- 235000017491 Bambusa tulda Nutrition 0.000 description 2
- 206010008909 Chronic Hepatitis Diseases 0.000 description 2
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 2
- 240000009118 Corylus chinensis Species 0.000 description 2
- 240000008397 Ganoderma lucidum Species 0.000 description 2
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 206010019663 Hepatic failure Diseases 0.000 description 2
- 206010019728 Hepatitis alcoholic Diseases 0.000 description 2
- 206010019799 Hepatitis viral Diseases 0.000 description 2
- 244000017020 Ipomoea batatas Species 0.000 description 2
- 235000002678 Ipomoea batatas Nutrition 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 244000082204 Phyllostachys viridis Species 0.000 description 2
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- 238000005273 aeration Methods 0.000 description 2
- 208000002353 alcoholic hepatitis Diseases 0.000 description 2
- 239000011425 bamboo Substances 0.000 description 2
- 235000017803 cinnamon Nutrition 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 238000009630 liquid culture Methods 0.000 description 2
- 208000007903 liver failure Diseases 0.000 description 2
- 231100000835 liver failure Toxicity 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 229910000160 potassium phosphate Inorganic materials 0.000 description 2
- 235000011009 potassium phosphates Nutrition 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 201000001862 viral hepatitis Diseases 0.000 description 2
- 235000020985 whole grains Nutrition 0.000 description 2
- KZMAWJRXKGLWGS-UHFFFAOYSA-N 2-chloro-n-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]-n-(3-methoxypropyl)acetamide Chemical compound S1C(N(C(=O)CCl)CCCOC)=NC(C=2C=CC(OC)=CC=2)=C1 KZMAWJRXKGLWGS-UHFFFAOYSA-N 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 244000111056 Chinese albizia Species 0.000 description 1
- 235000006481 Colocasia esculenta Nutrition 0.000 description 1
- 244000205754 Colocasia esculenta Species 0.000 description 1
- 240000008955 Dioscorea japonica Species 0.000 description 1
- 235000005251 Dioscorea japonica Nutrition 0.000 description 1
- 206010013911 Dysgeusia Diseases 0.000 description 1
- 235000009414 Elaeocarpus kirtonii Nutrition 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 241000222336 Ganoderma Species 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 244000062793 Sorghum vulgare Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 244000236151 Tabebuia pallida Species 0.000 description 1
- 235000013584 Tabebuia pallida Nutrition 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 241000143950 Vanessa Species 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000002391 anti-complement effect Effects 0.000 description 1
- 108010008730 anticomplement Proteins 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000021329 brown rice Nutrition 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000004464 cereal grain Substances 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 208000030304 gastrointestinal bleeding Diseases 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 235000019713 millet Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000003715 nutritional status Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 235000021075 protein intake Nutrition 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 235000019195 vitamin supplement Nutrition 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
【発明の詳細な説明】 (産業上の利用分野) 本発明は、肝機能障害者用食品に関するものである。[Detailed description of the invention] (Industrial application field) The present invention relates to a food for people with liver dysfunction.
(従来の技術)
肝機能疾患には、ウィルス性肝炎、アルコール性肝炎を
はじめとする肝炎や、肝硬変、肝不全等がある。ウィル
ス性肝炎、アルコール性肝炎4病状が悪化すると慢性肝
炎、さらには肝硬変へと進行する。肝硬変は肝不全ある
いは消化管出血などによる死の恐れを常に含んでいる。(Prior Art) Liver function diseases include hepatitis including viral hepatitis and alcoholic hepatitis, liver cirrhosis, liver failure, and the like. Viral hepatitis, alcoholic hepatitis 4 When the condition worsens, it progresses to chronic hepatitis and even cirrhosis. Liver cirrhosis always carries the risk of death due to liver failure or gastrointestinal bleeding.
このような重大な問題を肝機能障害の予防および改善と
いう目的で、医薬品の投与という方法としてでなく1食
の面からとりあげて解決しようとする試みも檀々なされ
てbる。例えば、「栄養改善法」に定められている「特
殊栄養食品」の「高蛋白質食品」や、いわゆる「健康食
品」等がある。For the purpose of preventing and improving liver dysfunction, many attempts have been made to solve these serious problems not by administering pharmaceuticals, but by focusing on single meals. For example, there are ``high-protein foods'' that are ``special nutritional foods'' stipulated in the ``Nutrition Improvement Act,'' and so-called ``health foods.''
「栄養改善法」は「国民の栄養改善思想を高め。The ``Nutrition Improvement Act'' aims to ``enhance the nation's idea of improving nutrition.
国民の栄養状態を明らかにし、かつ国民の栄gを改善す
る方途を講じて1国民の健康および体力の維持向上を図
り、もって国民の福祉の増進に寄与すること」を目的と
しており(栄養改善思想1条)。Its purpose is to clarify the nutritional status of the nation, take measures to improve the nation's prosperity, maintain and improve the health and physical strength of the nation, and thereby contribute to the promotion of the nation's welfare. Article 1 of Thought).
肝臓疾患のように蛋白質摂取量を多くする必要がある疾
患に適する食品として「高蛋白/X食品」がある。There are ``high protein/X foods'' that are suitable for diseases such as liver diseases that require increased protein intake.
込わゆる「健康食品」には、[物・動物性原料の抽出物
やビタミン剤等がある。これらは特定の栄養素による栄
養補助や健康増進等をう窺っている。"Health foods" include extracts of physical and animal ingredients, vitamin supplements, etc. These products allude to nutritional support and health promotion through specific nutrients.
抽出物を用いた例には、アマチャヅルサポニンを必須成
分としてなる「アマチャヅルサポニンを含む食品」があ
る(特開昭60−45558号公@i)。筐た。霊芝の
抽出物を必須成分とする「霊芝抽出物を含有する食品」
もある(特開昭60−34914号公:Ri)eh
(発明が解決しようとする問題点)
従来の「特殊栄誉食品」の「高蛋白質食品」は。An example of using an extract is a "food containing Jiaogulan saponin" which contains Jiaogulan saponin as an essential component (Japanese Patent Application Laid-Open No. 60-45558@i). It was a cabinet. "Food containing Reishi extract" which has Reishi extract as an essential ingredient
(Unexamined Japanese Patent Publication No. 60-34914: Ri) eh (Problem to be solved by the invention) The conventional "high-protein food" of the "special honor food" is.
肝ノ臓疾患患者など医師に多量の蛋白質摂取を指示され
た場合に限り、医−・栄養士等の相gk、指導を得て使
用する必要がある屯のである。「高蛋白質食品」は蛋白
質含jtt−通常の同種の食品の含量の2倍以上含有し
ているだけのものであり、多量にこれらの食品を摂取す
ることにより、各種の弊害が発生することもある。すな
わち、疾病の進行を止めているだけであって、積極的な
病態改善効果を目的としていない。まfc、単一食品で
あるので栄養バランスも整っていない。It should only be used under the guidance of a doctor or nutritionist if a doctor has instructed you to consume a large amount of protein, such as in patients with liver disease. "High-protein foods" are those that contain protein - more than twice the amount of normal similar foods, and consuming large amounts of these foods may cause various adverse effects. be. In other words, it merely halts the progression of the disease and is not intended to actively improve the condition. However, since it is a single food, it is not nutritionally balanced.
いわゆる「健康食品」は成分のはつきりしないものが多
く、病態改善効果を示唆するような表示をしているもの
でさえも、病態改善効果のある有効成分の存在は不明で
あり、病態改善効果も不明確である。成分分析を行なっ
ているような「健康食品」でも、日常食する食品として
の栄養バランスf病態改善効果をもつ有効成分の含有量
および品質の安定性に疑問をいだかせるもの力;多い。Many of the so-called "health foods" have unclear ingredients, and even if they are labeled to suggest that they have an effect on improving disease conditions, the existence of active ingredients that have the effect of improving disease conditions is unknown, and it is not clear whether they are effective in improving disease conditions. The effects are also unclear. Even for ``health foods'' whose ingredients have been analyzed, there are many questions about their nutritional balance as foods for daily consumption, the content of active ingredients that have the effect of improving pathological conditions, and the stability of their quality.
例えば、[アマチャヅルサポニンを含む食品」(t¥f
開昭60−45558号公報)はアマチャヅルから抽出
したアマチャヅルサポニンを必須成分として含む食品で
tb!+、血小板アラキドン酸の代謝抑制効果等の薬理
効果は期待できるが、病因改善に必要な他の栄養成分お
よび栄養バランスは不明であり、考慮されていない。For example, [foods containing Jiaogulan saponin] (t¥f
Publication No. 60-45558) is a food containing Jiaogulan saponin extracted from Jiaogulan as an essential ingredient. +, Although pharmacological effects such as the effect of suppressing the metabolism of platelet arachidonic acid can be expected, other nutritional components and nutritional balance necessary for improving the pathogenesis are unknown and have not been taken into account.
ま友、「盛運抽出物を含有する食品J(’%開餡60−
34914号公報)は、盗芝子実体の熱水抽出物をさら
に含酸素系有機溶媒で抽出しfcf+iI出物を必須成
分とする食品であり、アラキドン酸代謝物の抑制効果等
の薬理効果は期待できるが、病態改昏に必要な他の栄養
成分および栄養バランスは不明であシ、考慮されていな
い。Mayu, ``Food J containing Seiun extract ('% Kaian 60-
34914) is a food whose essential ingredient is the FCF+iI product obtained by further extracting the hot water extract of the fruiting body of Futoshiba with an oxygen-containing organic solvent, and it is expected to have pharmacological effects such as the suppressing effect on arachidonic acid metabolites. However, the other nutritional components and nutritional balance necessary to improve the disease are unknown and have not been taken into account.
本発明は、肝機能障害の病態改善効果と、これを補強す
る栄養補充効果とを兼備した肝機能1m害者用食品を提
供することにより、上記のごとき問題点1に′p16決
した。The present invention solves the above-mentioned problem 1 by providing a food for people with impaired liver function that has both the effect of improving the pathology of liver dysfunction and the effect of supplementing nutrients to reinforce this.
(DfU題点を解決するための手段)
本発明の肝機能障害者用食品は、マンネンタケ属Kfi
する担子菌と、穀類またはイモ類と、豆類とよ、り成り
、β−D−グルカンと、サポニンと。(Means for solving the DfU problem) The food for people with liver dysfunction of the present invention contains
It consists of basidiomycetes, cereals or potatoes, beans, β-D-glucan, and saponin.
エルゴステロールとを含有する発酵食品を用−ること′
に特徴とする肝機能障害者用食品である。Using fermented foods containing ergosterol
This is a food for people with liver dysfunction that is characterized by:
本発明者らは、(2E米の「特殊栄養食品」、「健康食
品」に見られる種々の問題点を考慮し、栄養成分にのみ
注視したり、4[物・動物性原料から抽出して得られる
有効成分を含有するエキスを混合しfcシして「健康食
品」とするのではなく、断交に病態改善用食品を得るこ
とを目的として開発を行ない、七の結果、得られ九マン
ネンタケ属に属する担子菌と穀類まfcはイモ類と豆類
とより成力。The present inventors (2E) took into account various problems seen in rice's "special nutritional foods" and "health foods," focused only on nutritional components, and Rather than mixing and FC-containing the obtained extracts containing the active ingredients to produce a "health food", we developed the product with the aim of obtaining a food for improving pathological conditions. The basidiomycetes and cereals that belong to this group are more productive than potatoes and legumes.
β−D−/ルカンとサポニンとエルゴステロールとを含
有する発酵食品が肝機能障害患者の病態改善効果を示し
たので1本発明を光取するに至つ友。The present invention was made because a fermented food containing β-D-/lucan, saponin, and ergosterol showed an effect on improving the pathology of patients with liver dysfunction.
また1本発明の肝機能障害者用食品は、蛋白質。In addition, the food for people with liver dysfunction according to the present invention contains protein.
炭水化物をはじめとする各種栄養成分もバランスよく含
有しており、病態改善効果とも合わせて。It also contains a well-balanced variety of nutritional components, including carbohydrates, and has the effect of improving disease conditions.
「特殊栄誉食品」とすることもできる。It can also be designated as a "special honor food."
マンネンタケ属の担子菌は、古くから身体に有用である
ことが知られ、%に厳近肝機能改善効果や、動脈硬化な
どにも効くということが知られてきた。The basidiomycete of the genus Cynthia has been known for a long time to be useful for the body, and it has been known that it is effective in improving liver function and is also effective against arteriosclerosis.
本発明に用いる発酵食品において使用するマンネンタケ
属の担子菌は、 tIJえは、マンネンタケ。The basidiomycetes of the genus C. monocytogenes used in the fermented food used in the present invention are: C. monocytogenes.
マゴジャクシ、ツガノマンネンタケ、シママンネンタケ
等の担子菌の菌糸体であり、好ましくはマンネンタケの
鉋糸体を使用する。It is the mycelium of a basidiomycete such as Physcomitrella chinensis, Physcomitrella chinensis, and Streptococcus chinensis, and preferably the cheloid body of Physcomitrella ultifolia is used.
本発明に用いる発酵食品は、炭素源として9A類または
イモ類、窒素源として豆類を用いた培地にマンネンタケ
属に属する担子菌を培#することにより得られる。The fermented food used in the present invention can be obtained by culturing a basidiomycete belonging to the genus Hemorrhoids in a medium using type 9A or potatoes as a carbon source and beans as a nitrogen source.
培地成分である穀類とイモ類と豆類は、)ffl常の食
品として利用される食品#(日本憚準食品成分表〔科学
技術庁貸諒調亘会鰯〕に記載の食品群〕より選ぶことに
エリ、最終的に得られる培養物を分離・抽出の操作を経
なくても、その1まで可食の状態とすることができる。The grains, potatoes, and beans that are the culture medium components should be selected from the food groups listed in the Food Composition Table of Japanese Foods [Japan Science and Technology Agency Rental Coordination Survey] that are used as regular foods. Finally, the final culture can be made edible without undergoing separation and extraction operations.
また1分離・抽出等の操作を加えなくてもよめために、
可食成分の持つ豊富な炭水化物や蛋白質等が、生体にと
って吸収されやすい物質に変化し、栄誉成分が損われる
ことなく残存している。In addition, in order to read without adding operations such as separation and extraction,
The abundant carbohydrates and proteins contained in edible ingredients are transformed into substances that are easily absorbed by the living body, and the honorable ingredients remain intact.
穀類としては、玄米、梢白木等の木、生そば、そば粉、
とうもろこし、あわ、えんばく、おおむき゛等全使用し
、好ましくは各檀形態の米、そば粉を使用する。Grains include brown rice, wood such as white wood, raw buckwheat, buckwheat flour,
Corn, millet, oat, oat, etc. are all used, and rice and buckwheat flour in each form are preferably used.
イモ類としては、さつまいも、じゃがいも、さといも、
長芋等を使用し、好ましくはさつ1いも’kf用する。Potatoes include sweet potatoes, potatoes, taro,
Use Japanese yam etc., preferably 1 sweet potato.
豆類としては、大豆あるいは脱脂大豆、きな粉などの大
豆製品等を使用し、好ましくは大豆を使用する。As the beans, soybeans, defatted soybeans, soybean products such as soybean flour, etc. are used, and soybeans are preferably used.
また、この可食培地は、穀類またはイモ類と豆類だけで
もよいが、グルコース、硫酸マグネシウム(食品添加物
用)、リン酸−カリウム(食品添加物用)を加えてもよ
い。しかし、町艮成分以外のものは含まない。Further, this edible medium may contain only cereals or potatoes and beans, but glucose, magnesium sulfate (for food additives), and potassium phosphate (for food additives) may also be added. However, it does not contain anything other than Machiwa ingredients.
マンネンタケ属の担子菌?この可食培地を用いて培養す
ることによって、不発EJAK用する発酵食品が得られ
る。A basidiomycete of the genus Cyrilium? By culturing using this edible medium, a fermented food for use in non-exploited EJAK can be obtained.
この発酵食品は1次のすべての特性を有する。This fermented food has all the properties of the first order.
(11制癌作用等の薬理効果を待つβ−D−グルカン倉
乾燥粉末状態で0.05〜10p/100f−粉末含有
する。このβ−D−グルカンは分岐鎖β−持つβ−(1
,5)−〇−グルカンであり、平均分子1は約108万
である。(11 β-D-glucan awaiting pharmacological effects such as anticancer effect) Contains 0.05 to 10p/100f-powder in the dry powder state. This β-D-glucan has β-(1
, 5)-〇-glucan, and the average molecule 1 is about 1,080,000.
(2) 抗補体活性作用、抗酸化作用等の薬理効果を
有するサポニンを乾燥粉末状態で0.05〜31/10
(M’−粉末含有する。(2) Saponin with pharmacological effects such as anti-complement activation and antioxidant effects in dry powder form from 0.05 to 31/10
(M'- Contains powder.
(31利尿効果等の薬理効果を有するエルゴステロール
を!li、床粉末状態で1.0〜100.OhQ /
100V−粉末含有する。(31 Ergosterol, which has pharmacological effects such as diuretic effect!li, 1.0 to 100.OhQ /
100V - Contains powder.
本発明に用いる発酵良品は1例えば、以下のような操作
で製造することができる。The fermented product used in the present invention can be produced, for example, by the following procedure.
炭水化物を多量に含む穀類ま友はイモ類の少なくとも一
棟からなる炭素源と、蛋白質を多量に含む豆類からなる
窒素源とを含有する可食成分のみで構成式れた培地で、
マンネンタケ属の担子菌の菌糸体の液体培養を行なう。Cereal Mayu, which contains a large amount of carbohydrates, is a medium composed only of edible ingredients, including a carbon source consisting of at least one tuber, and a nitrogen source consisting of beans containing a large amount of protein.
A liquid culture of basidiomycete mycelium of the genus C. chinensis is carried out.
培養条件は、培養温度上31〜45G、培1!液pHt
−2.5〜5.5.培池1を当り通気量を0.5〜2.
O2/順、樵菌接種筺全0.5〜20チとすることによ
り、4〜15日間で培養できる。このようにして得られ
友発酵生産切は、培養終了後の可食培地と菌糸体および
菌糸体生成物を培養液から分離しなめでその′1まで。The culture conditions are 31-45G above the culture temperature and 1! liquid pHt
-2.5 to 5.5. The aeration rate per culture pond 1 is 0.5 to 2.
By setting O2/order to 0.5 to 20 inoculated pots, culture can be carried out in 4 to 15 days. The fermentation product thus obtained is obtained by separating the edible medium, mycelium, and mycelium products from the culture solution after the cultivation is completed.
本発明に用いる発酵食品として利用できる。ま友は脱水
のみの加工を施して、有用成分を可能な限り多く含む発
酵食品とすることもできる。It can be used as a fermented food used in the present invention. Mayu can also be processed through dehydration to create a fermented food that contains as many useful ingredients as possible.
本発明の肝機能障害者用食品の摂取適量は1年齢1個人
差、症状などに影響されるので、場合によっては、下記
範囲外の量が適量となることもあるが、粉末を水筐友は
熱水、牛乳等に懸濁して摂取する場合、1日当り粉末2
0〜300fi、粉末12当り5〜1011Ltの水ま
たは熱水、牛乳等に@濁して、1回から3回に分けて6
ケ月以上飲用することが望ましい。The appropriate intake amount of the food for people with liver dysfunction of the present invention is influenced by age, individual differences, symptoms, etc. Depending on the case, the appropriate amount may be outside the range below. When suspended in hot water, milk, etc., take 2 powders per day.
0 to 300 fi, 5 to 1011 liters of water per 12 powders, suspended in hot water, milk, etc., divided into 1 to 3 times 6
It is recommended to drink it for more than a month.
(発明の効果)
本発明の肝機能障害者用食品は、少なくともβ−D−/
ルカンとサポニンとエルゴステロールという3種類の薬
理効果を持つ有効成分を含有しており、少なくともマン
ネンタケ属の担子菌の子実体に期待されると同程度以上
の病態改善効果を与える。また、担子菌と可食培地によ
り、蛋白質。(Effect of the invention) The food for people with liver dysfunction of the present invention has at least β-D-/
It contains three types of active ingredients with pharmacological effects: lucan, saponin, and ergosterol, and provides at least the same level of pathological improvement effect as expected from the fruiting bodies of the basidiomycete of the genus Stone. Also, basidiomycetes and edible media provide proteins.
炭水化物をはじめとする各種栄#成分もバランスよく含
まれておシ、病者用食品としての利用価値の高いものに
なっている。また、病態改善効果と合わせて「特殊栄養
食品」としても適したものである。It also contains various nutritional components such as carbohydrates in a well-balanced manner, making it highly useful as a food for the sick. In addition, it is suitable as a "special nutritional food" in addition to its ability to improve pathological conditions.
きらに、医学的・栄養的見地からみて、特別の栄養的配
Kを必要とする病者や、病態改善上目的とする場合のみ
でなく、肝炎等、肝機能障害の予防1食生活改@、健康
維持、体力向上の目的で用いること4でき、利用対象者
が広範囲である。マンネンタケの子実体やそのエキスで
は、マンネンタケ特有の強め苦味を有しており1通常の
食品としては利用しえない欠点があるが1本発明の肝機
能障害者用食品は、わずかな嗜好性のある苦味を有して
おり、かつ培地成分である食品材料が持っている風味も
損うことなくとどめているので1食品として適し次もの
である。ま7t、本発明に用いる発酵食品を液体培養に
ニジ得る場合には、製造条件を一定に保つことができ、
薬理効果のある有効成分および栄養成分の安定し九品質
のものが得られる。From a medical and nutritional point of view, it is recommended not only for patients who require special nutritional support or for the purpose of improving disease conditions, but also for the prevention of liver dysfunction such as hepatitis. It can be used for the purposes of maintaining health and improving physical strength, and can be used by a wide range of people. Although the fruiting body of C. chinensis and its extract have a strong bitter taste peculiar to M. chinensis, 1 it cannot be used as a normal food. It has a certain bitterness and retains the flavor of the food material, which is a medium component, without impairing it, so it is suitable as a food. 7t. When the fermented food used in the present invention is obtained in liquid culture, the manufacturing conditions can be kept constant;
Stable quality of active ingredients and nutritional ingredients with pharmacological effects can be obtained.
(実施例、試験例)
以下に実施例を示すが、本発明は、この実施例により限
定されるものではない。(Examples, Test Examples) Examples are shown below, but the present invention is not limited to these Examples.
ま友、試験例1.2に示すように、マンネンタケ属の担
子菌の菌糸体を、穀類まtはイモ類と豆類とを構成要素
とする培地を用いて培養することにより、得られる本発
明に用いる発酵食品に含有される蛋白質および糖質も、
構成要素の穀類ま几はイモ類と豆類とマンネンタケ属の
担子菌とをただ単に混合した場合に比べて、消化・吸収
されやすい形の遊離アミノ酸および単糖に分解されてお
り、消化能力の衰えた病者に適しfc*品となることが
わかる。As shown in Test Example 1.2, the present invention is obtained by culturing the mycelium of a basidiomycete of the genus Hemorrhoids using a medium containing grains or potatoes and beans as constituents. The proteins and carbohydrates contained in fermented foods used for
The component cereal grains are broken down into free amino acids and monosaccharides that are easier to digest and absorb than when potatoes, beans, and basidiomycetes of the genus Ganoderma are simply mixed, resulting in a decline in digestive ability. It can be seen that this is a fc* product suitable for sick people.
実施例
試験発酵槽を用Aて、マンネンタケ菌子体の培養を次の
と2力行なった。EXAMPLE Test Using a fermenter, culturing of the Mycobacterium mycelium was carried out in the following manner.
100を容の試験発酵槽中で、′g1表に示した可食培
地成分を水40tに溶解し、pHを4.0に調整し、1
20C2気圧で30分殺菌した。同じ組成の可食培地で
32’C14日間振盪培養して得九種菌糸培養物1.6
tを接種し友。培養温度を32’CK保ち、7日間通気
(404/l1il)攪拌(200r、pom、 )培
養すると粘稠な培養物が得られ次。これを凍結乾燥し粉
末1.5 kgを得友。この粉末は。In a test fermenter with a capacity of 100 g, the edible medium components shown in the table were dissolved in 40 t of water, the pH was adjusted to 4.0, and the
It was sterilized at 20C and 2 atm for 30 minutes. Nine species of mycelial culture 1.6 obtained by shaking culture for 32'C14 days in an edible medium with the same composition.
A friend who has been inoculated with T. A viscous culture was obtained by maintaining the culture temperature at 32'CK and culturing with aeration (404/l1il) and agitation (200r, pom, ) for 7 days. This was freeze-dried and 1.5 kg of powder was obtained. This powder.
されやかな風味とほのかな苦味t−有し1食品として適
し友ものであり、かつ第2表に示すような栄養成分およ
び有効成分を含んでい友。なシ、β−D−グルカンと大
豆サポニンはガスクロマトグラフィーによシ、エルゴス
テロールは高速液体クロマトグラフィーにより定量を行
なつtoこの粉末50g!に熱水(aoC)3oo−を
加えた粘稠な液体を、3回゛/日×6ケ月飲用すると。It has a mild flavor and a slight bitterness, making it suitable as a food, and it also contains the nutritional and active ingredients shown in Table 2. However, β-D-glucan and soybean saponin were determined by gas chromatography, and ergosterol was determined by high performance liquid chromatography using 50 g of this powder! If you drink a viscous liquid made by adding 3oo- of hot water (aoC) to the water, 3 times/day for 6 months.
漫性肝炎患者に改讐がみられ友。飲、用@後の患者の血
清トランスアミナーゼ1[を第3表に示し友。A friend who has found revenge in patients with chronic hepatitis. Table 3 shows the patient's serum transaminase levels after drinking and drinking.
第3表に示さnるように、CPT、GOTともに減少が
認められた。As shown in Table 3, a decrease was observed in both CPT and GOT.
第 1 表
I@2表
試績例1
マン浄ンタケ属の担子薗の一系体培養を行なうことによ
って、培地成分である633成分のうち蛋白質がどのよ
うに変化しているかを調べる定めに。Table 1 Table I @ Table 2 Experimental Example 1 We decided to investigate how proteins among the 633 components of the culture medium have changed by conducting a one-line culture of Basidizono of the genus Manjotake.
下記の試1ili1を行なった。The following trial 1ili1 was conducted.
大豆(全粒のまま) 50 f’i500tRt三角フ
ラスコに入れ、グルコース3.056.健dマグネシウ
ム0.1 %、 !77g−力!J ウA O,19
bf)mK(Dffl液3O−t−加え、120C2気
圧で20分殺菌する。Soybeans (whole grains) 50 f'i500tRt Place in Erlenmeyer flask and add glucose 3.056. Kend Magnesium 0.1%,! 77g-force! J U A O, 19
bf) Add 3O-t of mK (Dffl solution) and sterilize at 120C and 2 atm for 20 minutes.
このまま1糸体を加えずに、32Cで7日間静置し次後
、遠心分離により上清のみt−得る。これを試料Iとす
る。Without adding the strands, the mixture was allowed to stand at 32C for 7 days, and then centrifuged to obtain only the supernatant. This is designated as Sample I.
同様に大豆(全粒のまま)302を500−三角フラス
コに入れ、グルコース5.Os、aM7/ネシウム0.
1%、リン酸−カリウム0.1%の組底の溶液30wt
1に加え、120C2気圧で20分殺菌する。32Gま
で冷却後、水先により培地成分を*多#bたマンネンタ
ケ培養−糸体の植菌を8% (v/v )加える。32
Cで7日間静置培養した後、遠心分離により上清のみを
得る。これを試料■とする。Similarly, put 302 soybeans (whole grains) into a 500-Erlenmeyer flask, and put 5. Os, aM7/nesium 0.
1%, potassium phosphate-0.1% solution 30wt
In addition to step 1, sterilize at 120C and 2 atm for 20 minutes. After cooling to 32G, add 8% (v/v) of the inoculum of the ``Salthorn bamboo culture'' which was mixed with medium components using a water tip. 32
After static culture at C for 7 days, only the supernatant was obtained by centrifugation. This is designated as sample (■).
試料Iと試料■について溶液中の遊離アミノ酸を測定し
たところ、試料■の方が各アはノ酸とも増加しているこ
とがわかった。すなわち、マンネンタケ函糸体全混仕さ
せることにより、培地中の蛋白質が消化・吸収されやす
い形の遊離アミノ酸に分解されていることがわかった。When the free amino acids in the solutions of Sample I and Sample (2) were measured, it was found that Sample (2) had more amino acids than each other. In other words, it was found that by mixing the entire body of the Cinnamon mushroom box, the proteins in the culture medium were decomposed into free amino acids that were easily digested and absorbed.
その結果を第4表に示す。The results are shown in Table 4.
試験例2
マンネンタケ属の担子閑の1糸体培養を行なうことによ
って、培地成分である再食成分のうち糖質がどのように
変化しているかを調べる之めに。Test Example 2 In order to investigate how carbohydrates among the refeeding components, which are medium components, have changed by carrying out a monotonic culture of Basidiomyces spp.
下記の試験を行なった。The following tests were conducted.
デンプン5%、コーン・ステイープ・リカー2es、硫
酸マグネシウム0.1ts、リン酸−カリウム0.1%
の成分組成で培地を作成し、pHを4.0に6Affi
後、この溶液100dを500d坂ロフラスコに入れ、
120C2気圧で20分殺菌する。32Cまで冷却後、
水洗によって培地成分を取、り除い次マンネ/タケ培養
菌糸体を植菌として4%(v/V)加え、32cで8日
間振盪培養する。Starch 5%, corn steep liquor 2es, magnesium sulfate 0.1ts, potassium phosphate 0.1%
Create a medium with the composition of 6Affi and adjust the pH to 4.0.
After that, put 100 d of this solution into a 500 d slope flask,
Sterilize at 120C 2 atm for 20 minutes. After cooling to 32C,
The medium components were removed by washing with water, and then 4% (v/v) of manneum/bamboo cultured mycelium was added as an inoculum, and cultured with shaking at 32c for 8 days.
培養開始前と培養終了後の液から、遠心分離に上り上清
のみを得て、試料■および試料■とする。The liquid before the start of culture and after the end of culture is centrifuged to obtain only the supernatant, which is used as sample ① and sample ②.
試料■と試料■について、#液中の単糖とオリゴ砧の量
を測定したところ、試料■に比べて試料IVでは単糖が
増加していることがわかった。すなわち、マンネンタケ
菌糸体を混在さぜることにより。When the amount of monosaccharide and oligokinut in the #liquid was measured for sample (■) and sample (2), it was found that the amount of monosaccharide was increased in sample IV compared to sample (■). In other words, by mixing in the mycelium of Cinnamon mycelia.
培進中の多糖が消fヒ・吸収されやすい形の単糖に分解
されていることがわかつ友。その結果ヲ第5表に示す。A friend who knows that the polysaccharides in the culture are broken down into monosaccharides that are easily absorbed and decomposed. The results are shown in Table 5.
Claims (1)
、豆類とより成り、β−D−グルカンと、サポニンと、
エルゴステロールとを含有する発酵食品を肝機能障害者
用として用いることを特徴とする肝機能障害者用食品。Consisting of basidiomycetes belonging to the genus Hemorrhoids, grains or tubers, and beans, β-D-glucan, saponin,
A food for people with liver dysfunction, characterized in that a fermented food containing ergosterol is used for people with liver dysfunction.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP61074156A JPS62234026A (en) | 1986-04-02 | 1986-04-02 | Food for patient of hepatic function disorder |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP61074156A JPS62234026A (en) | 1986-04-02 | 1986-04-02 | Food for patient of hepatic function disorder |
Publications (1)
Publication Number | Publication Date |
---|---|
JPS62234026A true JPS62234026A (en) | 1987-10-14 |
Family
ID=13539010
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP61074156A Pending JPS62234026A (en) | 1986-04-02 | 1986-04-02 | Food for patient of hepatic function disorder |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS62234026A (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06312935A (en) * | 1993-04-30 | 1994-11-08 | Yukiguni Maitake:Kk | Production of substance having improving effect for liver disease |
JPH08266246A (en) * | 1995-03-29 | 1996-10-15 | Pawafuru Kenko Shokuhin Kk | Antimutagenic food |
JP2018104308A (en) * | 2016-12-22 | 2018-07-05 | 生展生物科技股▲分▼有限公司 | Liquid fermented products of ganoderma lucidum for use in improving symptoms of alcoholic liver disease, alcoholic fatty liver, and inflammation |
-
1986
- 1986-04-02 JP JP61074156A patent/JPS62234026A/en active Pending
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06312935A (en) * | 1993-04-30 | 1994-11-08 | Yukiguni Maitake:Kk | Production of substance having improving effect for liver disease |
JP2689244B2 (en) * | 1993-04-30 | 1997-12-10 | 株式会社雪国まいたけ | Method for producing liver disease improving agent |
JPH08266246A (en) * | 1995-03-29 | 1996-10-15 | Pawafuru Kenko Shokuhin Kk | Antimutagenic food |
JP2018104308A (en) * | 2016-12-22 | 2018-07-05 | 生展生物科技股▲分▼有限公司 | Liquid fermented products of ganoderma lucidum for use in improving symptoms of alcoholic liver disease, alcoholic fatty liver, and inflammation |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101164452B (en) | Double-preparation type composite mushroom functional beverage host and preparation method thereof | |
CN101164453B (en) | Composite mushroom functional beverage and preparation method thereof | |
TW201114373A (en) | Process for producing food products having a reduced content of purine compounds | |
JP2009528837A (en) | Functional fermented bubble beverage | |
CN105249100A (en) | Production method of fermented fruit and vegetable juice and Chinese rice wine composited function beverage | |
CN105077484A (en) | Phellinus igniarius flavored beverage and preparation method thereof | |
CN104146300A (en) | Compound Noni juice and preparation method thereof | |
Plygun et al. | Physicochemical, functional and sensory properties of acha-tamba based ogi enriched with hydrolysed soy peptides | |
CN106071867A (en) | A kind of preparation method of Flammulina velutiper (Fr.) Sing edible fungus flavor bean dregs foodstuff processing raw material | |
CN104382129A (en) | Beverage prepared from sweet corn and black tea fungus | |
KR101470949B1 (en) | Method for producing beverage adding shiitake extract and beverage produced by the same method | |
KR100894707B1 (en) | Fermented Bubble Drink with Functionality | |
JPS62234026A (en) | Food for patient of hepatic function disorder | |
CN110604179A (en) | Preparation method of lucid ganoderma and red date yoghourt | |
CN101658289A (en) | Preparing method of cordyceps sinensis dark soy sauce | |
JP2003063981A (en) | Nourishing tonic | |
JPS62234028A (en) | Food for patient of diabetes | |
JPS62234025A (en) | Food for senile dementia | |
JP6904594B2 (en) | Methods for Forming Iron-Enriched Nutritional Products | |
JPS59162842A (en) | Food and drink and its preparation | |
KR102165643B1 (en) | Concentrated liquid of glycosylated Lentinus edodes, Concentrated powder of glycosylated Lentinus edodes and Manufactured method of the same | |
TWI477236B (en) | A functional rice enriched with γ-aminobutyric acid and the manufacture method | |
KR102662657B1 (en) | Manufacturing method of sweet rice punch with cordycepin-contained brown rice and sweet brown rice punch and healthy drink thereby | |
CN107495111A (en) | A kind of health care fermented rice cake for preventing and treating high fat of blood and preparation method thereof | |
JPS6147180A (en) | Production of grain vinegar |